Diabetic retinopathy (DR), an obstacle of the visual microvascular system, is a serious complication of diabetic patients. Paraoxonase 1 (PON1) has been extensively evaluated as a genetic candidate for diabetic microvascular complications, and PON1 is associated with DR. In this study, the biological functions of PON1 and its related proteins were determined via gene ontology (GO) enrichment analysis; we demonstrated that treatment with resveratrol alleviated retinal inflammatory activities to evaluate its protective effects on streptozotocin (STZ)-induced diabetic rats and high-glucose (HG) stimulated rat retinal endothelial cells (RRECs). The GO enrichment analysis suggested that PON1 may regulate inflammatory responses and microvascular complications in DR. In an in vivo study, resveratrol significantly recovered the insulin level and PON1 expression and activity, as well as clearly reduced the retinal vascular permeability, retinal AGEs, LDL, Ox-LDL, caspase3 activity, retinal damage, IL-1β, IL-6, TNFα, VEGF, IFNγ and MCP-1 in STZ-diabetic rats. Moreover, resveratrol reduced the caspase3 activity and Ox-LDL expression in HG stimulated RRECs. However, its protective effect was a deficiency in PON1-silenced RRECs. PON1 is a pivotal modulator in the role of resveratrol in reversing the RREC damage induced by HG. Furthermore, we found that resveratrol exhibits an effect on attenuating the retinal inflammatory condition and damage of DR via PON1. Our study suggests that resveratrol-induced PON1 in the retina may be a promising therapeutic strategy to prevent diabetes-related retinopathy.
Introduction
As an obstacle of the visual microvascular system, diabetic retinopathy (DR) is a serious complication of diabetic patients (Song et al., 2018) and is recognized as the leading cause of blindness in workingage adults worldwide (Resnikoff et al., 2004; Song et al., 2018; Zheng et al., 2012) . The development of DR is related to persistent metabolic disorders, which are caused by increased blood levels of inflammatory cytokines and hyperglycemia (Rao and Dlouhy, 2012; Wykoff, 2017) . This systemic inflammation will lead to retinal microvascular leakage and edema, gradual retinal vascular basement membrane thickening, and pericyte loss (Behl et al., 2017; Miller et al., 2010) . Thus, the study of inflammation regulation will facilitate DR therapy.
Previous studies have demonstrated lipoprotein oxidation is involved in the development of coronary artery, cerebrovascular and microvascular complication diseases (Lyons et al., 1994; Luke et al., 2009; Morrison et al., 2008) . Paraoxonase (PON), a high-density lipoprotein (HDL) and low-density lipoprotein (LDL) associated enzyme, protects lipoproteins from oxidation (Draganov et al., 2005) , includingT lactonase and ester hydrolase, which catalyzes the hydrolysis of thiolactones and some xenobiotics, such as aromatic carboxylic esters, organophosphate esters, carbamates and unsaturated aliphatic esters (Costa et al., 2005; Davies et al., 1996) . PON2 reduces intracellular oxidative stress and apoptosis (Aviram and Rosenblat, 2004) . PON2 and PON3 only have the activity of lactonase (Draganov et al., 2005) . In humans, PON1 and PON3 are prevailingly expressed in the kidney and liver and are also detected in the blood (Jaouad et al., 2006; Leviev et al., 1997; Sierksma et al., 2002) . In contrast, the PON2 gene expression is relatively widespread; however, its protein product is not found in the blood circulation (Ng et al., 2001) . Previous studies have suggested that PON1 hydrolyses the pro-inflammatory oxidized phospholipids in LDL and HDL particles to protect against the induction of inflammation (Aviram et al., 1998; Camps et al., 2014; Watson et al., 1995) . PON1 has been evaluated as a genetic candidate of diabetic microvascular complications, and it is associated with the risk of DR (Barathi et al., 2010; Wang et al., 2013) .
Resveratrol (3,5,4′-trihydroxy-stilbene), a nonflavonoid polyphenolic compound, has been proven to be a good ROS scavenger for superoxide anions or singlet oxygen (Chang et al., 2011; Wang et al., 2014) , including processes and signaling pathways concerning cancer, obesity, diabetes, cardiovascular disorders, amyloidogenesis and others (Bitterman and Chung, 2015; Ciddi and Dodda, 2014; Patel et al., 2010; Quincozes-Santos et al., 2015; Truong et al., 2018; Zordoky et al., 2015) . With respect to eye diseases, studies have indicated its protective effects for age-related macular degeneration (Abu-Amero et al., 2016; Kang and Choung, 2016) . In this study, we demonstrated that resveratrol alleviated retinal inflammatory activities via PON1 to evaluate its protective effects on STZ-induced diabetic rats and a glucose-induced retinal endothelial cell damage model. Our study suggests that resveratrol-mediated PON1 in the retina is a promising treatment strategy to prevent diabetes-related retinopathy.
Materials and methods

Animals
Sprague-Dawley (SD) male rats (14 weeks old) were housed in standard stainless steel cages at 25°C and maintained under a 12 h light/dark cycle. The animal experiment was implemented in accordance with the Institutional Animal Care and Use Committee of Xi'an Peihua University.
Rat model of diabetes
Rats were treated with streptozotocin (STZ; Sigma-Aldrich, USA) (60 mg/kg, a single intravenous injection, dissolved in 1% citrate buffer (pH 4.5)) to induce the diabetic model, and the control rats received equivalent volumes of citrate buffer. After 72 h, glucose levels at 16.7 mmol/L or more, in addition to polyuria and other diabetic features were classified as diabetic. After 2 weeks of STZ injection, a subgroup STZ-diabetic rats were treated with an intravitreal injection of resveratrol (0.1 μg/mL or 1 μg/mL) in one eye and the contralateral eye served as the vehicle (PBS) in a volume of 5 μL, whereas the other rats were administered PBS or resveratrol (5, 10 or 50 μg/kg/d) via tail vein injection for 12 weeks. Normal rats were administered an equal volume of PBS.
Retinal vascular permeability analysis
The retinal vascular permeability analysis was performed with Evans blue assay. Rats were anesthetized and administered Evans blue dye (30 mg/kg) via femoral vein injection. To ensure the complete circulation of Evans blue dye, the rats were placed on a warm mat for 2 h after injection. The rats were perfused via the left ventricle with a solution of PBS followed by 4% paraformaldehyde. The eyes were enucleated, and the retinas were removed by manual dissection. The Evans blue dye was extracted in formamide and subsequently quantified by absorbance measurement at 420 nm.
Blood sampling and analysis
The rats were monitored daily, and the blood was drawn weekly from the tail vein for glucose and insulin determination. Blood glucose was measured by a Glucose Monitoring System (Johnson & Johnson, USA). The plasma samples were collected and detected via the Rat/ Mouse Insulin ELISA kit (Millipore, USA) and Cholesterol Assay Kit-HDL and LDL/VLDL (Abcam, USA). The experimental procedures were performed in accordance with the manufacturers' instructions.
Retinal advanced glycosylated end product (AGE) determination
The rats' eyes of the groups were obtained, and the left eye was used to measure the retinal AGEs. The retinas were lysed by RIPA buffer (Solarbio, China), and the supernatants were collected and then detected by a Rat AGE ELISA kit (MyBioSource, USA). The experimental procedures were performed in accordance with the manufacturers' instructions.
Rat retinal endothelial cell (RREC) culture
Cells were isolated as previously described (Chronopoulos et al., 2011) . RRECs were cultured in DMEM medium with 5 mM glucose (normal, N) or 30 mM glucose (high-glucose, HG), which was supplemented with 10% FBS and incubated at 37°C in the 5% CO 2 incubator. The RREC damage model was performed via HG stimulation for 7 days.
Transient transfection
RRECs were respectively transfected with PON1 Rat cDNA ORF Clone (Origene, China) or PON1 siRNA duplexes (Origene, China) according to the manufacturer's instructions. Following an infection of 48 h, the efficiency of the transfection was determined by qRT-PCR (in supplemental material).
Cell viability detection
To analyze the cell viability, WT or PON1 silenced RRECs were seeded 2 × 10 3 cells per 96-well plate. Overnight, the cells were treated with resveratrol (0, 10, 50, 100, 200 and 500 μM, respectively) for 24 h and incubated with 30 mM glucose or 5 mM glucose for 7 days, followed by the addition of 10 μl CCK8 (Dojindo, Japan). After 2-3 h, the OD 450 was measured using a Thermo MK3 (Thermo Scientific, USA).
qRT-PCR analysis
qRT-PCR was performed as previously described (Liu et al., 2018) : total RNA was isolated from eye tissues or RRECs and lysed in Trizol reagent (Invitrogen, USA); the total RNA was reversely transcripted to cDNA using a lnRcute lncRNA cDNA first strand synthesis Kit (Tiangen, China). q-PCR was performed using the FastFire qPCR Master Mix (Tiangen, China) and the CFX96TM Real-Time System (Bio-Rad, USA). GAPDH was amplified in parallel as an internal control. The primer sequences were as follows: PON1, Forward Primer: 5′-GTCGTGGTCCA ATGTTGTTTACT-3′, Reverse Primer: 5′-ACTTTCGATGACGTGCGTG-3'; EGFR, Forward Primer: 5′-AGCTCACGCAGTTGGGCA-3′, Reverse Primer: 5′-TCTCATGGGCAGCTCCTT-3'; bFGF, Forward Primer: 5′-AGCGGCTGTACTGCAAGAAC-3′, Reverse Primer: 5′-CAGTGCCACA TACCAACTGG-3'; and β-actin, Forward Primer: 5′-CGTGCGTGACATC AAAGAGAA-3′, Reverse Primer: 5′-GCTAGGAGCCAGAGCAGTAATC-3'.
WB analysis
Total protein was extracted from eye tissues or RRECs using RIPA lysis buffer (CST, USA) and detected through the BCA assay kit (Thermo, USA). The protein expression was detected by immunoprecipitation, incubated with primary antibodies to PON1 (Abcam, 1:500), Caspase 3 (CST, 1:800), cleaved-Caspase 3 (CST, 1:800) and GAPDH (Abcam, 1:2000) overnight at 4°C, followed by incubation with IRdye conjugated goat anti-rabbit IgG pAb (Li-COR) in the dark at 25°C for 1 h. The membrane was imaged in the Li-COR Odyssey Infrared Imaging System.
PON1 activity
The PON1 activity was determined as described by Assis et al. (2017) : the hydrolysis of paraoxon and the release of p-nitrophenol were measured, and the molar extinction coefficient of p-nitrophenol (18,000 M −1 cm −1 ) was calculated. The PON1 activity was expressed in units/liter (unit = μM paraoxon hydrolyzed/min).
TUNEL staining
The rats' eyes of the groups were enucleated; the cornea and lenses were removed, fixed with 4% paraformaldehyde for 2 h, dehydrated in 20-30% sucrose solutions and then embedded in Tissue-Tek OCT compound. They were snap-frozen at −80°C and sectioned 10 μm. TUNEL staining was subsequently performed with a Fluorescein in Situ Cell Death Detection Kit (Promega, USA). The experimental procedures were performed in accordance with the manufacturers' instructions.
ELISA kit for inflammatory factor in retina
Total protein was extracted from eye tissues or RRECs using RIPA lysis buffer. The levels of IL-1β, IL-6, TNFα, VEGF, IFNγ and MCP-1 in the supernatant were determined with Rat IL-1β, IL-6, TNFα, VEGF, IFNγ and MCP-1 ELISA Kits (Solarbio or R&D Systems), respectively; the level of Ox-LDL was determined with a Rat oxidized low-density lipoprotein, OxLDL ELISA Kit (MSK, Wuhan, China), according to the manufacturers' instructions.
GO enrichment analysis
As described by Zaman et al. the PON1 protein-protein interaction (PPI) data from the Biomolecular Interaction Network Database (BIND), Database of Interacting Proteins (DIP), Human Protein Reference Database (HPRD), Molecular INTeraction database (MINT), Protein-Protein Interaction Database for PDZ-domains (PDZBase) and STRING Database were collected to build a comprehensive background network (Zaman et al., 2014) . Cytoscape_v3.3.0 was used to cluster the network, and GO enrichment analysis in DAVID 6.7 (Database for Annotation, Visualization and Integrated Discovery) was used to annotate the biological functions.
Statistical analysis
Data are shown as the means ± SEM. Statistical analysis was performed using a one-way analysis of ANOVA followed by Tukey's multiple comparison test, with p < 0.05 considered significant. SPSS version 22.0 was used for all statistical analyses.
Results
Functional analysis of PON1 and its related proteins
To further interpret the complex relationships among the PON1-related proteins and pathways, the PPI network was constructed and analyzed. The human PPI data were collected to build a comprehensive background network. We clustered the network using Cytoscape_v3.3.0, and the biological functions were annotated. As shown in Fig. 1A , CLU and PON1 are coexpressed, APOA1, APOC3 and PON1 are gene coexpression, and the PON1-related main proteins are obtained from text mining and included CLU, APOA1, APOC3, ALB, LPA, IL6, APOE, Fig. 1 . Functional analyses of PON1 and its related proteins. (A) PON1 coexpression, gene coexpression, related proteins and pathways were clustered in the network using Cytoscape_v3.3.0; CLU and PON1 are co-expressed, APOA1 and PON1 and APOC3 and PON1 are gene coexpression, and PON1-related main proteins are from text mining and included ALB, LPA, IL6, APOE, APOA2, APOB, PPARA, HPR, SREBF2, and so on. (B, C) The biological functions were annotated utilizing biological processes of the GO enrichment analysis in DAVID 6.7. The functions were associated with cholesterol transport, the regulation of tau-protein kinase activity and cellular component maintenance. APOA2, APOB, PPARA, HPR, SREBF2, and so on (Fig. 1A) . The GO enrichment analysis indicated that PON1 and its coexpression, gene coexpression and related proteins were associated with cholesterol transport (such as the regulation of cholesterol transport, low-density lipoprotein particle remodeling and high-density lipoprotein particle clearance), the regulation of tau-protein kinase activity and cellular component maintenance (Fig. 1B and C) . Given that the regulation of cholesterol transport occupies ∼90% (Fig. 1C) and PON1 hydrolyses the pro-inflammatory oxidized phospholipids in LDL and HDL particles to protect against the induction of inflammation (Aviram et al., 1998; Camps et al., 2014; Watson et al., 1995) , we hypothesized that PON1 might regulate inflammatory responses and microvascular complications in DR.
Resveratrol regulated retinal vascular permeability and mRNA expression in vivo
We first examined the effect of resveratrol on the retinal vascular leakage in STZ-diabetic rats. After STZ-injection for 2 weeks, glucose was measured, and hyperglycemic rats were treated with an intravitreal injection of 0.1 μg/mL or 1 μg/mL of resveratrol in one eye and vehicle (PBS) in the contralateral eye. After 7 days, the Evans blue extravasation method was used to quantify the retinal vascular permeability. We identified a significant decrease (approximately 50%) in the retinal vascular permeability in the eyes treated with the 1 μg/mL dose of resveratrol ( Fig. 2A) . We also examined the effect of resveratrol on the expression of several pathogenic molecules in STZ-diabetic rats. After Fig. 2 . Resveratrol regulated retinal vascular permeability and mRNA expression. (A) At 2 weeks after STZ, blood glucose was measured, and hyperglycemic rats received an intravitreal injection of 0.1 μg/mL or 1 μg/mL of resveratrol in one eye and the vehicle (PBS) in the contralateral eye. After 7 days, retinal vascular permeability was quantified using the Evans blue extravasation method. (B-D) At 2 weeks after STZ injection, hyperglycemic rats received intravitreal injections of 0.1 μg/mL or 1 μg/mL of resveratrol in one eye and vehicle in the contralateral eye. At 24 h postinjection, the mRNAs of the target molecules of PON1, VEGF and bFGF were measured by qRT-PCR. (E-F) Blood LDL and HDL were measured, and 1 μg/mL of resveratrol significantly decreased the LDL level and increased the HDL level in STZ-diabetic rats. Data are shown as the means ± SEM, n = 5 per group. *p < 0.05, **p < 0.01, compared with vehicle. ##p < 0.01, compared with control.
STZ-injection for 2 weeks, hyperglycemic rats received intravitreal injections of 0.1 μg/mL or 1 μg/mL of resveratrol in one eye and vehicle in the contralateral eye. After 24 h injection, the mRNA expression was measured by qRT-PCR. Relative to the normal rats, the STZ-diabetic rats had a reduced expression of the proangiogenic factor PON1 (0.5-fold), and treatment with 1 μg/mL of resveratrol substantially induced PON1 mRNA (the level close to normal rats) (Fig. 2B) . Similarly, the angiogenesis-related factors VEGF and bFGF were upregulated in the STZ-diabetic rats' retinas, and treatment with 0.1 μg/mL or 1 μg/mL of resveratrol returned the factors to normal levels ( Fig. 2C and D) . The blood LDL clearly increased in the STZ-diabetic rats, and there was a clear decrease of LDL by resveratrol at 1 μg/mL (p < 0.01). Moreover, the blood HDL clearly decreased in the STZ-diabetic rats, and 1 μg of resveratrol restored the blood HDL level (p < 0.01) (Fig. 2E and F) .
Resveratrol improved STZ-diabetic rats
DR is a chronic and multifactorial disease, and it is accompanied by a gradual decline in visual function. To examine the long-term effects of resveratrol on visual function, STZ-diabetic rats were treated with resveratrol at 5, 10 or 50 μg/kg or vehicle for 12 weeks, with an equal volume of PBS administered in the normal group. During the study, the doses of resveratrol were safe, and there were no abnormal behaviors, adverse observations or deaths. After the 12-week treatment, the glucose level was significantly higher and the weight was significantly less in the STZ-diabetic rats than in the normal rats (Table 1) , while the resveratrol treatment groups did not exhibit significant weight loss. When treated with resveratrol, the glucose levels were clearly decreased by 25% at 5 μ/kg, 34% at 10 μ/kg, and 48% at 50 μ/kg (Table 1 ). It was determined that the Retinal AGEs in the 10 or 50 μ/kg resveratrol groups exhibited the same tendency as the glucose levels of the STZ-diabetic rats, which were decreased approximately 50% (Table 1 ). In addition, the insulin was significantly less in the STZdiabetic rats, while resveratrol significantly promoted the insulin levels (Table 1) . 
Resveratrol inhibited retinal apoptosis in vivo
Retinal apoptosis was detected by TUNEL staining. Retinas were collected within 3 h of the final administration of resveratrol and immediately processed for TUNEL staining. TUNEL-positive cells were stained with green fluorescence and observed in the retina, mostly located in the ONL of the STZ-diabetic rats (Fig. 3A) . STZ significantly increased the number of TUNEL-positive cells, and resveratrol clearly decreased the TUNEL-positive cells by approximately 30%, 44% and 48% at 5 μg/kg, 10 μg/kg and 50 μg/kg, respectively (p < 0.01, vs. vehicle) (Fig. 3B) .3.5 Resveratrol improved PON1 activity in vivo.
The PON1 activity in the retina was measured at the conclusion of the study. Individual retinas were collected within 3 h of the final administration of resveratrol and immediately processed for immunoblot assay. The PON1 activity was highest in the normal rats (Fig. 4A, B,  4D ). In the STZ-diabetic rats, the PON1 expression and activity were remarkable reduced to 0.17-fold. Following treatment with 10 μg/kg or 50 μg/kg resveratrol in the diabetic rats, the PON1 activity was substantially induced. For Ox-LDL, the STZ-diabetic rats had the highest 1.9-fold level, and resveratrol inhibited the oxidized lipids in LDL (Fig. 4E) ; treatment with 10 μg/kg or 50 μg/kg resveratrol showed significant differences compared with the vehicle of the STZ-diabetic rats. Retinal apoptosis was assessed according to the caspase3 activity. STZ caused a 6.1-fold augmentation of the cleaved-caspase3 expression compared with the normal group (Fig. 4C) . Resveratrol significantly decreased the cleaved-caspase3 level, with 50 μg/kg resveratrol in the STZ-diabetic rat retina treatment relative to the levels in the vehicletreated counterparts (Fig. 4C) .
Resveratrol reduced inflammatory factors in vivo
Several cytokines have been shown to be mediators that induce DR pathogenesis and increase in DR patients (Semeraro et al., 2015) . We examined the cytokine expression profile in the retina to determine whether resveratrol mediated PON1 functions to negatively regulate the inflammatory pathway. At the conclusion of the study, retinal tissues were collected separately within 3 h after the final tail vein injection and analyzed by ELISA kits. We showed that inflammatory cytokines were upregulated in the retina of the STZ-diabetic rats treated with vehicle alone, and resveratrol had a profound effect on downregulating all examined cytokines in the retina (Fig. 5A-F) . We determined that the downregulation of several cytokines by resveratrol are upregulated in the ocular tissue of human patients with DR, including IL-1β, IL-6, TNFα, VEGF, INFγ and MCP-1. Therefore, these results suggest that resveratrol decreases the levels of inflammatory cytokines in the retina.
Resveratrol protected against high glucose-stimulated injury and inflammatory via PON1 in vitro
To demonstrate resveratrol protected the retina through PON1, WT, PON1-siRNA or PON1-overexpressed RRECs were stimulated with HG and treated with resveratrol or vehicle. The transfection efficiency was determined by qRT-PCR and is shown in Fig. S . siRNA decreased the PON1 gene expression by approximately 72%, and overexpression promoted the PON1 gene expression by approximately 2.8-fold. Under normal conditions, a low dose of resveratrol (< 100 μM) had no damage to the RREC viability, while resveratrol reduced the RREC viability at 200 μM and 500 μM (Fig. 6A) . HG (30 mM) significantly inhibited the RREC viability, and resveratrol reduced this damage. PON1 silencing increased the damage that was induced by HG and reduced the protection of resveratrol on RRECs (Fig. 6B) . The WB results showed that HG reduced the PON1 expression and induced high cleaved-caspase3; these effects were more obvious in the PON1-siRNA RRECs and Fig. 5 . Resveratrol reduced inflammatory factor in retina. At the conclusion of the study, retinal tissues were collected separately within 3 h after the final tail vein injection, and the levels of IL-1β (A), IL-6 (B), TNFα (C), VEGF (D), IFNγ (E) and MCP-1 (F) were analyzed via ELISA kits. Data are shown as the means ± SEM, n = 5 per group. *p < 0.05, **p < 0.01, compared with vehicle. #p < 0.05, ##p < 0.01, compared with normal. less in the PON1-overexpressed RRECs (Fig. 6C) . Resveratrol reversed the cleaved-caspase3 expression, PON1 expression and PON1 activity caused by HG; however, PON1 silencing aggravated the cleaved-caspase3 expression and weakened the inhibition of resveratrol on the cleaved-caspase3 and PON1 activities in RRECs (Fig. 6D and E) . In addition, the ox-LDL level was suppressed by resveratrol through PON1 in HG induced RRECs (Fig. 6F) . Consistent with the results of the in vivo animal experiments, resveratrol suppressed IL-1β, IL-6, TNFα, VEGF, INFγ and MCP-1 with dose-dependence, while this inhibitory effect was counteracted by PON1 silencing in RRECs (Fig. 7A-F) . These findings implied that PON1 might be a pivotal modulator in the role of resveratrol protection.
Discussion
It has been reported that lipoprotein oxidation was involved in the development of the microvascular complications of diabetes (Khanam et al., 2017) . Ox-LDL is crucial for microvascular lesions (Palazhy and Viswanathan, 2017) , and the ingestion of this modified lipoprotein is produced by scavenging receptors found on macrophages, which leads to the production of foam cells, a marker of microvascular disease (Assis et al., 2017; Steinberg and Witztum, 2010) . Ox-LDL also has an effect on hyperoxic anion free radical production and smooth muscle vascular remodeling to cause endothelial dysfunction (Assis et al., 2017; Galle et al., 2006; Samani Keihan et al., 2016) . PON1 degrades oxidized lipids in LDL and inhibits the synthesis of Ox-LDL. A therapeutic intervention controls hyperglycemia and promotes PON1 levels, which provide additional protection against long-term diabetic complications (Assis et al., 2017) . In this study, we demonstrate that systemic PON1 improved and Ox-LDL decreased by resveratrol delays and reduces the retinopathy of STZ-diabetic rats. In addition, resveratrol protected RRECs from high glucose stimulation via PON1 in vitro.
The diabetic hyperglycemic environment is considered a risk factor for retinopathy formation, inflammation, and vascular defects. Effective control of blood glucose is the key to prevent or reverse diabetic complications and improve the life quality of patients with diabetes (Lo et al., 2014) . AGEs are localized to the retinal vasculature and vascular endothelial cells (Tzeng et al., 2016; Yoo and Kim, 2016) and contribute to adjusting the ECM function and elaboration of cytokines, and they are directly associated with retinal neuronal cell apoptosis (Palozza et al., 2012) . Furthermore, an AGE selective inhibitor can prevent acellular capillaries, retinal microaneurysms, and pericyte loss in diabetic dogs (Erejuwa et al., 2014; Tzeng et al., 2016) . It has been reported that resveratrol successfully lowers the blood glucose levels and retinal AGEs, whereas it enhances the insulin levels in STZ-diabetic rats (Liu, 2003) . The concentration of blood glucose and insulin is considered a good indicator for diabetes diagnosis and prognosis (Lee et al., 2006) . Thus, resveratrol's antidiabetic properties make it a complementary therapy that may reduce the complications of diabetes. We demonstrated that resveratrol exhibited AGE inhibitor properties in retinal tissue.
The development of DR is associated with sustained metabolic disorders caused by hyperglycemia and increased levels of chronic inflammation (Wykoff, 2017) . The chronic inflammation caused by these metabolic alternations leads to hemodynamic changes, BRB damage, increased retinal vascular permeability and edema (Wykoff, 2017) . IL-1β is upregulated in the retina of diabetic rats during the acute phase of the disease (Liu et al., 2012; Scuderi et al., 2015) . High levels of TNFα are detected in the vitreous of diabetic animal models and patients (Joussen et al., 2009 ). Additional cytokines have been shown to be associated with DR through animal models and clinical evidence in the eyes of diabetic patients, including growth-related oncogene, IL-6, MCP-1, and IL-8 (Bromberg-White et al., 2013; Lange et al., 2011) . Previous studies show that PON1 drives the expression of inflammatory cytokines in the retinas of diabetic mice. Importantly, we show that resveratrol in STZ-diabetic rats decreases many of the inflammatory cytokines below the levels, and resveratrol provides therapeutic benefits to delay and reduce retinopathy, despite the ongoing hyperglycemia in resveratrol treated STZ-diabetic rats. Thus, similar to previous studies, this study suggests that retinal inflammation is a primary Fig. 7 . Resveratrol reduced inflammatory factor in RRECs. WT or PON1 silenced RRECs were stimulated with 30 mM glucose and treated with different concentrations of resveratrol (10, 50 and 100 μM); the levels of IL-1β (A), IL-6 (B), TNFα (C), VEGF (D), IFNγ (E) and MCP-1 (F) were analyzed via ELISA kits. Data are shown as the means ± SEM, n = 4 per group. &&p < 0.01, compared with normal (N). *p < 0.05, **p < 0.01, compared with vehicle. #p < 0.05, ##p < 0.01, compared with normal. $$p < 0.01, compared with 100 μM resveratrol + HG + siRNA. mechanism that drives retinopathy in DR. GO enrichment analysis indicates that PON1 and its related proteins are associated with cholesterol transport, the regulation of tau-protein kinase activity and cellular component maintenance (Ikhlef et al., 2016 (Ikhlef et al., , 2017 . Moreover, numerous reports have also indicated cholesterol disorder can induce inflammatory cytokine expression in the retina (Hu et al., 2014; Tian et al., 2017) and is a potential risk factor for retinopathy (Acharya et al., 2017; Saadane et al., 2016; Zekavat et al., 2017) . PON1 may play a vital role in DR, and resveratrol can regulate inflammation via PON1. In addition, anti-VEGF therapy via intravitreal injection treatment has the characteristics of high costs and side effects. Furthermore, these therapies require relatively frequent injections, which may be prohibitive to long-term care because of compliance. Resveratrol provides the distinct therapeutic advantage of being a natural product that effectively reaches the retina following oral systemic administration. In STZ-diabetic rats, resveratrol reduces VEGF and bFGF expression and decreases retinal vascular permeability. Resveratrol may be used in anti-VEGF and anti-inflammatory therapy in DR. Furthermore, silencing and overexpression verify that PON1 reduces the caspase3 activity in RECs, and the effect of resveratrol reverses high glucose stimulation, which is defeated in PON1 silenced RRECs. Thus, PON1 is a pivotal modulator in the role of resveratrol to protect RRECs from high glucose stimulation.
Metformin, a well-known anti-diabetic agent, is very effective in type 2 diabetes. Metformin elicits its therapeutic effects mainly via the activation of the AMPK pathway and pathologic pathways, such as NF-κB, mTOR, endoplasmic reticulum (ER) stress, epithelial-to-mesenchymal transition (EMT), oxidative stress, and hypoxia (Ravindran et al., 2017; Xu et al., 2017) . Furthermore, it is reported that Metformin protects against retinal cell death in diabetic (Kim et al., 2017) mice and might also exert its effect against diabetic complications by increasing PON1 activity and decreasing Ox-DLD (Wójcicka et al., 2016) . We demonstrated resveratrol induced PON1 expression and activity and reduced Ox-DLD, retinal AGEs, inflammatory cytokines (IL-1β, IL-6, TNFα, IFNγ, MCP-1 and VEGF) and retinal damage in STZ-diabetic rats. Resveratrol also reduced Ox-DLD and RREC apoptosis through increasing PON1 activity in vitro. These findings suggest that resveratrol may exert its effects through PON1 to achieve these functions. We believe resveratrol has rich biological activity, and the adjustment of DR is a multifaceted mechanism.
In summary, our data show resveratrol exhibits an effect on attenuating the retinal inflammatory condition and the damage of DR via PON1. Further studies are warranted to explore the clinical application of resveratrol for the treatment of diabetic retinopathy.
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